Astellas Pharma revenue and financials
¥2,255.50Change from previous close: +0.53%Absolute change: +¥12.00
In the fiscal year ended March 2026, Astellas Pharma reported revenue of ¥2.14T (+11.87% year over year). Net income was ¥291.54B, a net margin of 13.6%.
Fiscal year ending in March. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +11.87%
- FY to Mar 2026 vs FY to Mar 2025
- Net income growth
- +474.49%
- FY to Mar 2026 vs FY to Mar 2025
- Net margin
- 13.6%
- FY to Mar 2025: 2.7%
Financial data
Amounts in millions of JPY; per-share values in JPY; shares in millions.
| Item | Q1 2026 | Q1 2025 |
|---|---|---|
| Total assets | 3,567,042 | 3,339,544 |
| Current assets | 1,421,923 | 1,201,349 |
| Cash and equivalents | 281,605 | 188,372 |
| Short-term investments | 9,572 | 29,941 |
| Inventory | 331,014 | 297,261 |
| Net property, plant and equipment | 358,424 | 328,921 |
| Goodwill | 441,175 | 415,207 |
| Other intangible assets | 996,932 | 1,123,714 |
| Long-term investments | 20,297 | 18,989 |
| Current liabilities | 1,218,401 | 1,061,610 |
| Accounts payable | 199,752 | 187,840 |
| Long-term debt | 320,000 | 564,893 |
| Total debt | 565,952 | 831,426 |
| Total liabilities | 1,736,158 | 1,826,289 |
| Total equity (incl. minority) | 1,830,884 | 1,513,255 |
| Retained earnings | 902,836 | 740,939 |
| Minority interest | 1,840 | 0.0 |